Suzuken (9987) Q3 2025 earnings summary

Executive summary

• Revenue and profit increased, driven by anti-cancer and specialty drug market expansion, more specialty drug contracts, and a smaller-than-expected decline in COVID-19-related product sales.

• Operating income rose 12.4% year-over-year to ¥29,799 million, supported by higher revenue and cost control initiatives.

• Net income attributable to owners surged 20.3% year-over-year to ¥30,672 million, aided by extraordinary gains from the sale of investment securities.

• The company is executing a medium-term management plan focused on reforming existing businesses and preparing for new growth areas, including digital health and specialty drug distribution.

• Full-year earnings forecast remains unchanged due to uncertainty from upcoming price negotiations.

Financial highlights

• Consolidated net sales for 3Q FY2024 were ¥1,838.7 billion, up ¥24.3 billion year-over-year (1.3%).

• Operating income rose to ¥29.8 billion, up ¥3.3 billion YoY (12.4% growth).

• Net income attributable to owners was ¥30.7 billion, up ¥5.2 billion YoY (20.3% growth).

• Extraordinary gains totaled ¥13,005 million, mainly from gains on sales of investment securities.

• Net assets decreased to ¥413,760 million as of December 31, 2024, from ¥416,428 million at March 31, 2024, due to dividends, share repurchases, and market valuation changes.

Outlook and guidance

• Full-year net sales forecast is ¥2,391,000 million, a 0.2% increase year-over-year.

• Operating income is projected at ¥33,600 million (down 3.7% YoY), and net income attributable to owners at ¥34,300 million (down 10.6% YoY).

• Full-year earnings forecast is unchanged, reflecting uncertainty from future price negotiations with some clients in the second half.